Autoreactive B Cells in Membranous Nephropathy

NCT04095156 · tracked via the Priya Life Science Italy tracker

Sponsor

Mario Negri Institute for Pharmacological Research

Phase

Observational

Started

2019-09-25

Last updated

2026-03-20

Condition(s) studied

Membranous Nephropathy

Investigational drug(s) / intervention(s)

In vitro assays.

In vitro assays.: Biochemical and flow-cytometry analysis of specimen collected.

Study summary

Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 receptor (PLA2R). Infusion of anti-CD20 monoclonal antibodies results in a profound depletion of B-cells, which are thought to be responsible for anti-PLA2R production. B-cell depletion is followed by NS remission in 70% of cases. Limited evidence highlighted that differences in the B- and T-cell compartments may exist between responders and non-responders. Owing to the non-homogenous efficacy of anti-CD20 treatment, investigators hypothesize that in MN patients who experience NS remission after B-cell depleting therapy, autoreactive B-cells may be mostly circulating, whereas in patients who do not respond to the same treatment, autoreactive B-cells may chiefly reside into secondary lymphoid organs - and thus be more resistant to the drug action. Researchers will therefore extensively analyze the circulating immune repertoire of MN patients before and after the infusion of B-cell lineage depleting agents, assessing the presence of circulating PLA2R autoreactive B cells from appropriately stratified responder and non-responder patients. Patients and healthy controls will be enrolled in this study. Patients will be stratified according to gender, anti-PLA2R status, type of B-cell lineage depleting agent received and response to treatment.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: Patients inclusion criteria * Males and females. * Adults (\> 18 years old). * Patients with biopsy-proven idiopathic MN, who are candidate to receive (prospective cohort) or who already received (retrospective cohort) a B-cell depleting treatment as per center clinical practice. * Mental state is such that they are able to understand and give valid consent to the study; * Written informed consent according to the guidelines of the Declaration of Helsinki. Healthy volunteers inclusion criteria * Male and female (\>18 years) not known to suffer of any significant illness; * Not assuming any medication or drug on a regular basis; * Negative urine analysis (urine dipstick, multistick); * Written informed consent according to the guidelines of the Declaration of Helsinki Exclusion Criteria: Patients exclusion criteria * Reasonable possibility of a secondary cause of MN (e.g.systemic lupus erythematosus, active hepatitis B, malignancy, drugs such as gold salts and penicillamine). * Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent. Healthy volunteers exclusion criteria \- Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.

Primary outcome measure(s)

Differences between anti-PLA2R positive MN patients and anti-PLA2R negative MN patients and healthy controls in the frequency of anti-PLA2R autoreactive circulating B-cells. — Changes from baseline and 3,6,9,12 and 24 month.
Differences between anti-PLA2R positive MN patients and anti-PLA2R negative MN patients and healthy controls in the frequency of immunoglobulin- and cytokine-secreting circulating B-cell subsets in resting and stimulated conditions. — Changes from baseline and 3,6,9,12 and 24 month.
Differences between anti-PLA2R positive MN patients and anti-PLA2R negative MN patients and healthy controls in spontaneous / stimulated immunoglobulin (including anti-PLA2R) and cytokine release from circulating B-cell subpopulations. — Changes from baseline and 3,6,9,12 and 24 month.
Differences between MN patients and healthy controls, and between responders and non-responders in the frequency of circulating B-cell subpopulations. — Changes from baseline and 3,6,9,12 and 24 month.
Differences between MN patients and healthy controls, and between responders and non-responders in the frequency of circulating T-cell, NK-cell, monocyte and dendritic cell subpopulations. — Changes from baseline and 3,6,9,12 and 24 month.

Trial sites (1)

Facility	City	Region	Status
Centro di Ricerche Cliniche per le Malattie Rare " Aldo e Cele Daccò"	Ranica	BG	Recruiting

More Mario Negri Institute for Pharmacological Research trials in Italy

Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (ASST Papa Giovanni XXIII) Active, not recruiting

Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study Active, not recruiting

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases Recruiting

Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care Recruiting

Health-care Quality in Semi-intensive Care Units Recruiting

Other trials for the same condition

Omics of Rituximab-resistance Starting soon

An Outcome Analysis of Primary Membranous Nephropathy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04095156 on ClinicalTrials.gov ↗ ← All trials in Italy